Gelatin capsule market seen reaching $7.01 billion by 2030

The Business Research Company says the gelatin capsule market is on track to grow from $4.92 billion in 2025 to $7.01 billion by 2030, driven by pharmaceutical manufacturing, nutraceutical demand and new capsule technologies. Asia-Pacific held the largest share in 2025 and is expected to remain the fastest-growing region.

Why it matters: - Gelatin capsules remain a core drug-delivery format for pharmaceuticals, vitamins and supplements. - The market’s projected climb to $7.01 billion by 2030 points to sustained demand for easy-to-swallow, dose-accurate and stability-focused delivery systems. - The shift toward plant-based alternatives, controlled-release products and higher-bioavailability formulations could reshape capsule manufacturing.

What happened: - The Business Research Company released a gelatin capsule market segmentation analysis focused on growth opportunities through 2030. - The report estimates the market will rise from $4.92 billion in 2025 to $5.27 billion in 2026. - The report forecasts a 7.1% compound annual growth rate in 2026. - The market is projected to reach $7.01 billion by 2030 at a 7.4% CAGR. - The report says Asia-Pacific held the largest market share in 2025 and is expected to be the fastest-growing region during the forecast period.

The details: - Gelatin capsules are dosage forms made from gelatin or plant-based substitutes that encase medicines, supplements and nutraceutical ingredients. - The capsule format is designed to support precise dosing, easier swallowing and improved bioavailability. - Gelatin capsules also help protect active ingredients from moisture, oxygen and light. - Growth through 2026 is linked to rising pharmaceutical manufacturing, oral drug delivery systems, demand for easy-to-use dosage forms, wider use in vitamins and supplements, global generic drug production and automation in capsule manufacturing. - Growth through 2030 is tied to nutraceutical and functional food demand, vegan capsule alternatives, precision medicine, controlled-release formulations, global pharmaceutical production and attention to drug stability. - The report highlights plant-derived capsule materials, advanced modified-release technologies, encapsulation demand in dietary supplements, coating methods that protect against moisture and oxygen, and high-bioavailability formulations for personalized medicine. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis, future trend analysis and updated graphics and tables. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The market forecast reflects two overlapping demand drivers: traditional pharmaceutical growth and consumer interest in supplements and plant-based products. - Asia-Pacific’s lead suggests manufacturing capacity and consumer demand are both concentrated in the region. - The emphasis on stability, bioavailability and modified release shows capsule makers are competing on performance, not just volume. - Eurostat reported in April 2025 that EU exports of medicinal and pharmaceutical products rose 13.5% in 2024 from 2023, reaching $316.38 billion (€313.4 billion), while imports rose 0.5% to $112.7 billion (€119.7 billion).

What's next: - The market will likely see more plant-derived capsule materials as vegan and nutraceutical demand grows. - Capsule makers are expected to keep investing in coating, modified-release and precision-medicine applications. - Regional growth in Asia-Pacific will remain a key signal for global production and supply-chain planning.

The bottom line: - Gelatin capsules are moving from a mature dosage form to a more specialized delivery platform, with growth increasingly tied to supplements, plant-based alternatives and advanced drug-release technologies.